Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention.
BACKGROUND
Thrombin generation (TG) is a central step of the coagulation system involved in hemostatic and thrombotic roles. Scarce data evaluating in the acute phase the association between TG and the risk of cardiovascular death of acute coronary syndrome (ACS) patients are available, in the era of percutaneous coronary intervention (PCI) and stenting with the use of dual antiplatelet treatment.


METHODS
We investigated TG in 292 ACS patients undergoing PCI with stent implantation on dual antiplatelet treatment. Venous samples were obtained 12-24h after PCI. TG was assessed using the Calibrated Automated Thrombogram (CAT).


RESULTS
At two years of follow-up, 57 out of 292 patients (19.5%) died from cardiovascular causes. Higher values of endogenous thrombin potential (ETP) [1115.9 (705-1441.3) vs 940.2 (666.0-1253.1), p=0.049], peak [176.1 (80.5-259.4) vs 107.3 (59.9-181.1), p=0.002] and velocity index [61.75 (21.03-97.88) vs 25.64 (11.95-50.90), p<0.001] were observed in relation to survival patients. At the multivariate model adjusted for the Global Registry of Acute Coronary Events risk score, the association between TG and cardiovascular death remained significant for ETP [OR (95% CI): 2.58 (1.10-6.03), p=0.029], peak [OR (95%CI): 3.27 (1.35-7.92), p=0.009] and velocity index [OR (95% CI): 3.06 (1.27-7.39), p=0.013]. This result was confirmed after adjustment for high on-treatment platelet reactivity [ETP: OR (95% CI) 2.35 (1.11-5.00), p=0.027; peak: OR (95% CI) 2.42 (1.13-5.15), p=0.022; velocity index: OR (95% CI) 2.43 (1.14-5.20), p=0.022].


CONCLUSIONS
ACS patients with a residual TG after PCI and stent implantation have a significantly higher risk of long-term cardiovascular death. These results might be useful in improving risk stratification for ACS patients and support the need of a tailored antithrombotic therapy.
Department Experimental and Clinical Medicine, University of Florence, Italy; Careggi University Hospital, Florence, Italy. Electronic address: monica.attanasio@unifi.it.
Monica
M
Attanasio
Department Experimental and Clinical Medicine, University of Florence, Italy; Careggi University Hospital, Florence, Italy.
Rossella
R
Marcucci
Department Experimental and Clinical Medicine, University of Florence, Italy; Careggi University Hospital, Florence, Italy; Don Gnocchi Foundation, Florence, Italy.
Anna Maria
AM
Gori
Department Experimental and Clinical Medicine, University of Florence, Italy; Careggi University Hospital, Florence, Italy.
Rita
R
Paniccia
Careggi University Hospital, Florence, Italy.
Serafina
S
Valente
Epidemiology Unit, ASF Tuscany Region, Piero Palagi Hospital, Florence, Italy.
Daniela
D
Balzi
Epidemiology Unit, ASF Tuscany Region, Piero Palagi Hospital, Florence, Italy.
Alessandro
A
Barchielli
Careggi University Hospital, Florence, Italy.
Nazario
N
Carrabba
Careggi University Hospital, Florence, Italy.
Renato
R
Valenti
Careggi University Hospital, Florence, Italy.
David
D
Antoniucci
Don Gnocchi Foundation, Florence, Italy; University of Florence, Italy; CESMAV, Florence, Italy.
Rosanna
R
Abbate
Don Gnocchi Foundation, Florence, Italy; University of Florence, Italy; CESMAV, Florence, Italy.
Gian Franco
GF
Gensini
D054058:Acute Coronary Syndrome / Q000097:blood / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012306:Risk; D015607:Stents / Q000009:adverse effects; D013917:Thrombin / Q000032:analysis* / Q000378:metabolism; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D013917:Thrombin
Coronary disease; Mortality; Myocardial infarction; Thrombin